BACKGROUND: Asthma is considered to be associated with elevated levels of exhaled nitric oxide (FeNO). The nature of this relationship and how it is influenced by atopy are still not resolved. METHODS: The Isle of Wight birth cohort (N=1456) was reassessed at 18 years of age. Participants able to attend the research centre were assessed by questionnaires, skin prick testing and FeNO in order to explore the interrelationship between asthma, atopy and FeNO. RESULTS: Atopy was significantly associated with higher levels of FeNO. However, the level of FeNO for non-atopic asthmatic participants was no different to the non-atopic no-asthma group. The highest levels of FeNO were seen in subjects with both atopy and asthma. In addition, FeNO was positively associated with increasing atopic burden as evidenced by increasing FeNO with increasing skin prick testing positivity, and with increasing severity of atopic asthma as evidenced by the number of attacks of wheezing. FeNO and current inhaled corticosteroid use were not significantly associated. CONCLUSIONS: FeNO behaves as a biomarker of atopy and the "allergic asthma" phenotype rather than asthma itself. This may explain why FeNO-guided asthma treatment outcomes have proved to be of limited success where atopic status has not been considered and accounted for.
BACKGROUND:Asthma is considered to be associated with elevated levels of exhaled nitric oxide (FeNO). The nature of this relationship and how it is influenced by atopy are still not resolved. METHODS: The Isle of Wight birth cohort (N=1456) was reassessed at 18 years of age. Participants able to attend the research centre were assessed by questionnaires, skin prick testing and FeNO in order to explore the interrelationship between asthma, atopy and FeNO. RESULTS: Atopy was significantly associated with higher levels of FeNO. However, the level of FeNO for non-atopic asthmatic participants was no different to the non-atopic no-asthma group. The highest levels of FeNO were seen in subjects with both atopy and asthma. In addition, FeNO was positively associated with increasing atopic burden as evidenced by increasing FeNO with increasing skin prick testing positivity, and with increasing severity of atopic asthma as evidenced by the number of attacks of wheezing. FeNO and current inhaled corticosteroid use were not significantly associated. CONCLUSIONS:FeNO behaves as a biomarker of atopy and the "allergic asthma" phenotype rather than asthma itself. This may explain why FeNO-guided asthma treatment outcomes have proved to be of limited success where atopic status has not been considered and accounted for.
Authors: Justin Travers; Suzanne Marsh; Sarah Aldington; Mathew Williams; Philippa Shirtcliffe; Alison Pritchard; Mark Weatherall; Richard Beasley Journal: Am J Respir Crit Care Med Date: 2007-05-03 Impact factor: 21.405
Authors: Mariëlle W Pijnenburg; E Marije Bakker; Wim C Hop; Johan C De Jongste Journal: Am J Respir Crit Care Med Date: 2005-06-23 Impact factor: 21.405
Authors: D Venkataraman; M Erlewyn-Lajeunesse; R J Kurukulaaratchy; S Potter; G Roberts; S Matthews; S H Arshad Journal: Clin Exp Allergy Date: 2018-02-08 Impact factor: 5.018
Authors: Louise Fleming; Lemonia Tsartsali; Nicola Wilson; Nicolas Regamey; Andrew Bush Journal: Am J Respir Crit Care Med Date: 2013-08-01 Impact factor: 21.405
Authors: Adrian Chan; William Terry; Hongmei Zhang; Wilfried Karmaus; Susan Ewart; John W Holloway; Graham Roberts; Ramesh Kurukulaaratchy; Syed Hasan Arshad Journal: Clin Exp Allergy Date: 2018-02 Impact factor: 5.018
Authors: Colin L Robinson; Lauren M Baumann; Karina Romero; Juan M Combe; Alfonso Gomez; Robert H Gilman; Lilia Cabrera; Guillermo Gonzalvez; Nadia N Hansel; Robert A Wise; Kathleen C Barnes; Patrick N Breysse; William Checkley Journal: Thorax Date: 2011-07-05 Impact factor: 9.139
Authors: Stephanie Lovinsky-Desir; Kyung Hwa Jung; Andrew G Rundle; Lori A Hoepner; Joshua B Bautista; Frederica P Perera; Steven N Chillrud; Matthew S Perzanowski; Rachel L Miller Journal: Environ Res Date: 2016-09-29 Impact factor: 6.498
Authors: Douglas C Cowan; D Robin Taylor; Laura E Peterson; Jan O Cowan; Rochelle Palmay; Avis Williamson; Jef Hammel; Serpil C Erzurum; Stanley L Hazen; Suzy A A Comhair Journal: J Allergy Clin Immunol Date: 2014-12-06 Impact factor: 10.793